Debjani Grenier

2.3k total citations
19 papers, 823 citations indexed

About

Debjani Grenier is a scholar working on Oncology, Genetics and Family Practice. According to data from OpenAlex, Debjani Grenier has authored 19 papers receiving a total of 823 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 5 papers in Genetics and 3 papers in Family Practice. Recurrent topics in Debjani Grenier's work include BRCA gene mutations in cancer (3 papers), Cancer Treatment and Pharmacology (3 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Debjani Grenier is often cited by papers focused on BRCA gene mutations in cancer (3 papers), Cancer Treatment and Pharmacology (3 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Debjani Grenier collaborates with scholars based in Canada, United States and Brazil. Debjani Grenier's co-authors include Davinder S. Jassal, Jonathan R. Walker, Tielan Fang, Nazanin Fallah‐Rad, Iain D. C. Kirkpatrick, Anthony Wassef, Marianne Krahn, Sheena Bohonis, Pawan K. Singal and Matthew Lytwyn and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Debjani Grenier

18 papers receiving 804 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Debjani Grenier Canada 11 442 407 290 84 81 19 823
Yat Yin Lam Hong Kong 10 535 1.2× 315 0.8× 67 0.2× 4 0.0× 134 1.7× 16 690
Nazanin Fallah‐Rad Canada 9 823 1.9× 335 0.8× 460 1.6× 2 0.0× 99 1.2× 37 997
Daniella Bovelli Italy 6 354 0.8× 276 0.7× 115 0.4× 2 0.0× 93 1.1× 13 504
Christelle Jouannaud France 11 206 0.5× 488 1.2× 238 0.8× 2 0.0× 148 1.8× 52 762
Kara Laing Canada 12 29 0.1× 274 0.7× 44 0.2× 15 0.2× 114 1.4× 26 537
Kelsey C. Stoltzfus United States 12 102 0.2× 360 0.9× 95 0.3× 2 0.0× 224 2.8× 17 745
M. Ryberg Denmark 7 221 0.5× 268 0.7× 52 0.2× 3 0.0× 126 1.6× 13 479
Renske Altena Sweden 11 279 0.6× 225 0.6× 111 0.4× 103 1.3× 31 603
Elliot J. Mitmaker Canada 19 47 0.1× 228 0.6× 47 0.2× 6 0.1× 111 1.4× 32 971
Teresa Halbsguth Germany 15 140 0.3× 443 1.1× 84 0.3× 181 2.2× 25 971

Countries citing papers authored by Debjani Grenier

Since Specialization
Citations

This map shows the geographic impact of Debjani Grenier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Debjani Grenier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Debjani Grenier more than expected).

Fields of papers citing papers by Debjani Grenier

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Debjani Grenier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Debjani Grenier. The network helps show where Debjani Grenier may publish in the future.

Co-authorship network of co-authors of Debjani Grenier

This figure shows the co-authorship network connecting the top 25 collaborators of Debjani Grenier. A scholar is included among the top collaborators of Debjani Grenier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Debjani Grenier. Debjani Grenier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Gandhi, Sonal, Muriel Brackstone, Nicole J. Look Hong, et al.. (2022). A Canadian national guideline on the neoadjuvant treatment of invasive breast cancer, including patient assessment, systemic therapy, and local management principles. Breast Cancer Research and Treatment. 193(1). 1–20. 15 indexed citations
2.
Araújo, Daniel Vilarim, Kerry J. Savage, Tina Cheng, et al.. (2021). CANDIED: A Pan-Canadian Cohort of Immune Checkpoint Inhibitor-Induced Insulin-Dependent Diabetes Mellitus. Cancers. 14(1). 89–89. 11 indexed citations
3.
Hsu, Tina, Flávia De Angelis, Sanraj Basi, et al.. (2021). Ten ways to get a grip on designing and implementing a competency-based medical education training program. SHILAP Revista de lepidopterología. 12(2). e81–e87. 8 indexed citations
4.
Araújo, Daniel Vilarim, Kerry J. Savage, Tina Cheng, et al.. (2021). Pan-Canadian cohort of immune checkpoint inhibitor-induced insulin-dependent diabetes mellitus (CANDIED).. Journal of Clinical Oncology. 39(15_suppl). 2640–2640. 1 indexed citations
5.
Schaid, Daniel J., Celine M. Vachon, Andrew Cooke, et al.. (2020). Impact of Personalized Genetic Breast Cancer Risk Estimation With Polygenic Risk Scores on Preventive Endocrine Therapy Intention and Uptake. Cancer Prevention Research. 14(2). 175–184. 10 indexed citations
6.
7.
Schaid, Daniel J., Andrew Cooke, Christina Kim, et al.. (2019). Impact of a breast cancer (BC) polygenic risk score (PRS) on the decision to take preventive endocrine therapy (ET): The Genetic Risk Estimate (GENRE) trial.. Journal of Clinical Oncology. 37(15_suppl). 1501–1501. 4 indexed citations
8.
Arnaout, Angel, Karen A. Gelmon, Brigitte Poirier, et al.. (2018). Neoadjuvant Therapy for Breast Cancer: Updates and Proceedings From the Seventh Annual Meeting of the Canadian Consortium for Locally Advanced Breast Cancer. Current Oncology. 25(5). 490–498. 15 indexed citations
9.
Graham, Jeffrey, Marshall Pitz, Vallerie Gordon, et al.. (2016). Clinical predictors of benefit from fulvestrant in advanced breast cancer: A Meta-analysis of randomized controlled trials. Cancer Treatment Reviews. 45. 1–6. 17 indexed citations
10.
Niraula, Saroj, et al.. (2016). Abstract P5-14-02: Clinical predictors of benefit from fulvestrant in advanced breast cancer: A meta-analysis of randomized controlled trials. Cancer Research. 76(4_Supplement). P5–14. 1 indexed citations
11.
Graham, Jeffrey, Debjani Grenier, & Arjuna Ponnampalam. (2014). Metastatic Breast Cancer in a Patient with Fanconi Anemia. Blood. 124(21). 5164–5164.
12.
Hack, Thomas F., Joseph D. Ruether, Lorna Weir, Debjani Grenier, & Lesley F. Degner. (2012). Promoting consultation recording practice in oncology: identification of critical implementation factors and determination of patient benefit. Psycho-Oncology. 22(6). 1273–1282. 29 indexed citations
13.
14.
Hack, Thomas F., Joseph D. Ruether, Lorna Weir, Debjani Grenier, & Lesley F. Degner. (2011). Study protocol: Addressing evidence and context to facilitate transfer and uptake of consultation recording use in oncology: A knowledge translation implementation study. Implementation Science. 6(1). 20–20. 9 indexed citations
15.
Grenier, Debjani, Andrew Cooke, Lisa M. Lix, et al.. (2010). Bone mineral density and risk of postmenopausal breast cancer. Breast Cancer Research and Treatment. 126(3). 679–686. 25 indexed citations
16.
Partridge, Ann H., Laura Archer, Alice B. Kornblith, et al.. (2010). Adherence and Persistence With Oral Adjuvant Chemotherapy in Older Women With Early-Stage Breast Cancer in CALGB 49907: Adherence Companion Study 60104. Journal of Clinical Oncology. 28(14). 2418–2422. 106 indexed citations
17.
Wadhwa, Deepa, Nazanin Fallah‐Rad, Debjani Grenier, et al.. (2008). Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study. Breast Cancer Research and Treatment. 117(2). 357–364. 113 indexed citations
18.
Partridge, A. H., Laura Archer, Alice B. Kornblith, et al.. (2008). CALGB 60104: Adherence with adjuvant capecitabine among women age 65 and older with early stage breast cancer treated on CALGB 49907. Journal of Clinical Oncology. 26(15_suppl). 6542–6542. 6 indexed citations
19.
Gelmon, Karen A., John R. Mackey, Shailendra Verma, et al.. (2004). Use of Trastuzumab Beyond Disease Progression: Observations from a Retrospective Review of Case Histories. Clinical Breast Cancer. 5(1). 52–58. 104 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yat Yin Lam Breakdown of academic impact, for papers by Nazanin Fallah‐Rad Breakdown of academic impact, for papers by Daniella Bovelli Breakdown of academic impact, for papers by Christelle Jouannaud Breakdown of academic impact, for papers by Kara Laing Breakdown of academic impact, for papers by Kelsey C. Stoltzfus Breakdown of academic impact, for papers by M. Ryberg Breakdown of academic impact, for papers by Renske Altena Breakdown of academic impact, for papers by Elliot J. Mitmaker Breakdown of academic impact, for papers by Teresa Halbsguth
Rankless by CCL
2026